Horizon Therapeutics (HZNP) Tops Q1 EPS by 20c; Maintains Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Horizon Therapeutics plc Reports First-Quarter 2022 Financial Results
May 4, 2022 7:00 AM EDT
First-Quarter 2022 Results:
-- Net Sales of $885.2 Million --
-- GAAP Net Income of $204.3 Million; Adjusted EBITDA of $371.2 Million --
-- TEPEZZA® (teprotumumab-trbw) Net Sales of $501.5 Million --
-- KRYSTEXXA® (pegloticase injection) Net Sales of $140.7 Million --
-- Cash Position of $1.64 Billion as of March 31, 2022 --
Full-Year 2022 Guidance:
-- Maintaining Full-Year 2022 Net Sales Guidance of $3.9 Billion to $4.0 Billion, Representing 22% Growth at the Midpoint --
-- Maintaining Full-Year 2022 Adjusted EBITDA Guidance of $1.63... More
